{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:16:38Z","timestamp":1791209798872,"version":"4.1.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0121207","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T18:06:06Z","timestamp":1426269966000},"page":"e0121207","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["HP1\u03b2 Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy"],"prefix":"10.1371","volume":"10","author":[{"given":"Young-Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuming","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Ann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,13]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1593\/tlo.12244","article-title":"Gene signatures in breast cancer: current and future uses","volume":"5","author":"EE Arranz","year":"2012","journal-title":"Translational oncology"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrc1670","article-title":"Breast cancer metastasis: markers and models","volume":"5","author":"B Weigelt","year":"2005","journal-title":"Nature reviews Cancer"},{"issue":"6871","key":"ref3","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"LJ van 't Veer","year":"2002","journal-title":"Nature"},{"issue":"6797","key":"ref4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"CM Perou","year":"2000","journal-title":"Nature"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/path.2648","article-title":"The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade","volume":"220","author":"B Weigelt","year":"2010","journal-title":"The Journal of pathology"},{"issue":"7418","key":"ref6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/bcr2852","article-title":"Stratifying triple-negative breast cancer: which definition(s) to use?","volume":"13","author":"B Adamo","year":"2011","journal-title":"Breast cancer research: BCR"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/carcin\/bgq069","article-title":"BRCA1 and BRCA2: breast\/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair","volume":"31","author":"PJ O'Donovan","year":"2010","journal-title":"Carcinogenesis"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of &apos;BRCAness&apos; in sporadic cancers","volume":"4","author":"N Turner","year":"2004","journal-title":"Nature reviews Cancer"},{"issue":"16","key":"ref10","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"N McCabe","year":"2006","journal-title":"Cancer research"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","article-title":"Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations","volume":"10","author":"KJ Dedes","year":"2011","journal-title":"Cell cycle"},{"issue":"7035","key":"ref12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"HE Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"ref13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"H Farmer","year":"2005","journal-title":"Nature"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"PC Fong","year":"2009","journal-title":"The New England journal of medicine"},{"key":"ref15","article-title":"Differential Chemotherapeutic Sensitivity for Breast Tumors With &quot;BRCAness&quot;: A Review","author":"P Chalasani","year":"2013","journal-title":"The oncologist"},{"issue":"9737","key":"ref16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","volume":"376","author":"A Tutt","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1093\/nar\/gkt231","article-title":"HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response","volume":"41","author":"YH Lee","year":"2013","journal-title":"Nucleic acids research"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0959-437X(00)00058-7","article-title":"The HP1 protein family: getting a grip on chromatin","volume":"10","author":"JC Eissenberg","year":"2000","journal-title":"Current opinion in genetics & development"},{"issue":"23","key":"ref19","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1007\/s00018-005-5287-9","article-title":"Heterochromatin protein 1: a pervasive controlling influence","volume":"62","author":"K Hiragami","year":"2005","journal-title":"Cellular and molecular life sciences: CMLS"},{"issue":"24","key":"ref20","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1128\/MCB.01048-09","article-title":"The emerging role of HP1 in the DNA damage response","volume":"29","author":"C Dinant","year":"2009","journal-title":"Molecular and cellular biology"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1083\/jcb.200904033","article-title":"Revisiting the role of heterochromatin protein 1 in DNA repair","volume":"185","author":"AR Ball Jr.","year":"2009","journal-title":"The Journal of cell biology"},{"issue":"9369","key":"ref22","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(03)13308-9","article-title":"Gene expression predictors of breast cancer outcomes","volume":"361","author":"E Huang","year":"2003","journal-title":"Lancet"},{"issue":"25","key":"ref23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"MJ van de Vijver","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1073\/pnas.0409462102","article-title":"Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival","volume":"102","author":"HY Chang","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1021\/jm801171j","article-title":"Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer","volume":"52","author":"TD Penning","year":"2009","journal-title":"Journal of medicinal chemistry"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"RM Neve","year":"2006","journal-title":"Cancer Cell"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1158\/1535-7163.MCT-11-0597","article-title":"Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models","volume":"11","author":"CC Clark","year":"2012","journal-title":"Molecular cancer therapeutics"},{"issue":"36","key":"ref28","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","article-title":"Reporting recommendations for tumor marker prognostic studies","volume":"23","author":"LM McShane","year":"2005","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"1\u20132","key":"ref29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mrfmmm.2008.09.007","article-title":"Linking Heterochromatin Protein 1 (HP1) to cancer progression","volume":"647","author":"GK Dialynas","year":"2008","journal-title":"Mutation research"},{"issue":"13","key":"ref30","first-page":"3359","article-title":"Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer","volume":"60","author":"DA Kirschmann","year":"2000","journal-title":"Cancer research"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/emmm.200900022","article-title":"Heterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology","volume":"1","author":"L De Koning","year":"2009","journal-title":"EMBO molecular medicine"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/bcr2834","article-title":"Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis","volume":"13","author":"B Keam","year":"2011","journal-title":"Breast cancer research: BCR"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2407-13-148","article-title":"HP1gamma expression is elevated in prostate cancer and is superior to Gleason score as a predictor of biochemical recurrence after radical prostatectomy","volume":"13","author":"J Slezak","year":"2013","journal-title":"BMC cancer"},{"issue":"7403","key":"ref34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"C Curtis","year":"2012","journal-title":"Nature"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"T Scholzen","year":"2000","journal-title":"Journal of cellular physiology"},{"issue":"28","key":"ref36","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"A Urruticoechea","year":"2005","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/cncr.11188","article-title":"Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors\u2014a surrogate marker?","volume":"97","author":"H Trihia","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/annonc\/mdq732","article-title":"Is the Ki-67 labelling index ready for clinical use?","volume":"22","author":"W Jonat","year":"2011","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","article-title":"Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry","volume":"139","author":"EC Inwald","year":"2013","journal-title":"Breast cancer research and treatment"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","article-title":"Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients","volume":"96","author":"E de Azambuja","year":"2007","journal-title":"British journal of cancer"},{"issue":"12","key":"ref41","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1046\/j.1365-2443.2002.00596.x","article-title":"Interaction of the chromatin compaction-inducing domain (LR domain) of Ki-67 antigen with HP1 proteins","volume":"7","author":"A Kametaka","year":"2002","journal-title":"Genes Cells"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.1016","article-title":"The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher-order chromatin structure","volume":"196","author":"T Scholzen","year":"2002","journal-title":"The Journal of pathology"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"e30042","DOI":"10.1371\/journal.pone.0030042","article-title":"BRCAness profile of sporadic ovarian cancer predicts disease recurrence","volume":"7","author":"WZ Wysham","year":"2012","journal-title":"PloS one"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1634\/theoncologist.2012-0028","article-title":"BRCAness: finding the Achilles heel in ovarian cancer","volume":"17","author":"G Rigakos","year":"2012","journal-title":"The oncologist"},{"issue":"22","key":"ref45","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2010.28.5791","article-title":"Personalizing therapy for ovarian cancer: BRCAness and beyond","volume":"28","author":"RC Bast Jr.","year":"2010","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0124853","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T00:00:00Z","timestamp":1428883200000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0121207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T21:12:16Z","timestamp":1598821936000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0121207"}},"subtitle":[],"editor":[{"given":"Brij","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,13]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0121207","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0124853","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,13]]}}}